Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And so, if they go into clinical trials, not only would our customers benefit, but we'll benefit through the exposure that they get from the U.S |
| We remain focused on improving the value of Dyadic for the life science industry, which will in turn improve value for shareholders and improve access to affordable vaccines and therapeutics globally |
| C1 is now completed a Phase 1 human trial with favorable preliminary safety data and has the capability to produce larger quantities of proteins at lower cost and in less time than the traditional eukaryotic gene expression platform used today |
| We now have the initial analytics demonstrating how recombinant albumin is comparable to commercialized reference samples on the market today, which improves our ability to commercialize a research-grade product in the coming year |
| Our third vertical of alternative proteins continues to be an area of great excitement for Dyadic and one which we believe also holds their term potential promise in terms of opportunity and revenue |
| We believe the success of our corporate strategy is beginning to be realized as evidenced by our September announcement of an agreement inclusive of upfront fees, and positive data from our first in human Phase 1 study, and our recently announced advancements in our own internal recombinant serum albumin projects, which have accelerated opportunities to enter into additional collaborations and partnerships, such as the memorandum of understanding with the Italian government's foundation, Biotecnopolo di Siena, which performs the functions of an anti-pandemic hub with a particular focus on the development and production of vaccines and monoclonal antibodies for the treatment of emerging epidemic and pandemic pathologies, and the recently announced research collaboration with vaccine and immunotherapy center in Massachusetts General Hospital |
| We're happy to see C1 is gaining more recognition globally within academia, government and industry |
| We're continuing to validate the C1 platform to reduce clinical development risk for our partners and adding to our strong repository of safety, efficacy and productivity data regarding the C1 platform across a wide range of vaccines and antibodies |
| By increasing the volume of internal pipeline products and external partnerships across our verticals, we believe we can accelerate more consistent revenue generation in the coming year that is not strictly reliant on platform licensing and inclusive of potential product licensing for targets such as recombinant albumin, enzyme catalysts or cell culture media components |
| Dyadic’s microbial platforms have a long history of economically producing large-scale bioindustrial proteins and enzymes, which we are leveraging to manufacture biopharmaceutical proteins with upstream costs and quantities that are closer to industrial margins, providing our collaborators improved pricing flexibility |
| Advancements to both our C1 and Dapibus platforms further enhance the speed, quality and productivity of these cell lines for targeted product opportunities, such as increasing our infectious disease antigen library to include seasonal and pandemic influenza, new COVID variants, rabies, as well as other antigens and antibodies as potential product opportunities for the C1 platform |
| This is why the C1 protein production platform is uniquely suited to meet the rising demand for vaccines, monoclonal antibodies, therapeutics and other proteins |
| We've also gained significant traction with our Dapibus platform, which was launched less than 12 months ago in both the alternative protein and bio-industrial markets |
| We've accelerated the momentum seen in the first half of 2023 as our C1 technology continues to garner praise and recognition for its speed and efficiency in the U.S |
| The agreement we signed in September to utilize our Dapibus platform to develop and commercialize certain non-animal dairy enzymes used in production of food products demonstrates the potential for our Dapibus platform to deliver results as well as the increased interest in this segment |
| This is why we believe our C1 filamentous fungal protein production platform has distinct advantages versus traditional eukaryotic cell lines currently used to manufacture vaccines and biologic drugs |
| To further support revenue growth, we have initiated development of additional pipeline projects, which is cell culture media and other proteins and enzymes across our core verticals at different grades and price points for multiple applications in pharmaceutical and non-pharmaceutical markets, which we believe will improve our capability to drive near-term revenues |
| We continue to believe that our C1 platform is well positioned to be an alternative platform in developing and manufacturing next generation vaccines, antibodies and other therapeutic proteins for public health and future pandemics |
| Animal health continues to be an attractive segment for Dyadic due to the higher margin sensitivity of pharmaceutical biologics and the significant impact and an outbreak can have on the global supply chain and potentially human health |
| The interest in ferritin-based nanoparticle vaccines has been increasing due to their ability to enhance immunogenicity, and C1 can produce these ferritin nanoparticles in a one-step manufacturing process, as opposed to the current two-step method used by other technologies, potentially improving the speed and cost effectiveness of the production process |
| You've done a wonderful job |
| Hopefully what we share today instills the same enthusiasm and confidence that the Dyadic leadership team has in the company's future growth potential |
| Very good |
| While this is encouraging, it is also why we have our foundation of microbial platforms is not just important, but also valuable |
| We believe that we are at or near the precipice of applying our microbial protein production platforms, C1 and Dapibus, to develop antigens, antibodies, enzymes and other proteins across each of our core verticals that we believe will lead to monetization that can significantly increase shareholder value for Dyadic and our collaborators |
| We will continue to leverage our decades of commercial scale industrial manufacturing knowledge and experience to accelerate near-term product development opportunities across our core verticals |
| We have made further progress in developing animal-free recombinant serum albumin products that have demonstrated analytical comparability to commercially available reference samples, bringing us another step closer to commercialization and monetization |
| He's had an immediate impact illustrated by a significant increase in unique client engagements and a 300% increase in new followers in the last 45 days versus the 45 days preceding his hire on a leading social networking app |
| What makes a particular platform an ideal choice for commercialization is one that is also rapid, highly productive and cost-effective |
| It also provides potential opportunities for larger sub-exit options, such as joint ventures or spin-offs, as products like recombinant albumin have been the foundation for companies such as Albumedix, which was purchased in 2022 for over GBP400 million |
| Statement |
|---|
| Research and development revenue and the license revenue for the third quarter of 2023 decreased to approximately $397,000 compared to $880,000 for the same period a year ago |
| The decrease in revenue and cost of revenue for the quarter was due to several research projects winding down or on hold as a result of our lab relocation at one of our major contract research organizations |
| Cost of research and development revenue for the quarter decreased to approximately $106,000 compared to $603,000 for the same period a year ago |
| Net loss for the quarter was approximately $1,614,000 or $0.06 per share compared to $1,809,000 or $0.06 per share for the same period a year ago |
| I think my question just got answered, because I see that you're burning about $500,000 a month negative cash flow and that was my exact question |
| Net loss for the nine months was approximately $4,724,000 or $0.16 per share compared to $7,589,000 or $0.27 per share for the same period a year ago |
| Our projection for our annual cash burn of 2023 will be less than $6 million |
| The decrease primarily reflected the winding down activity related to the company's phase one clinical trial of DYAI-100's COVID-19 vaccine candidate as patient dosing was completed in February 2023 |
| Research and development expenses for the quarter decreased to approximately $716,000 compared to $744,000 for the same period a year ago |
| Research and development expenses for the nine months year-to-date decreased to approximately $2,444,000 compared to $3,917,000 for the same period a year ago |
| G&A expenses for the quarter decreased by 7.3% to approximately $1,282,000 compared to $1,383,000 for the same period a year ago |
Please consider a small donation if you think this website provides you with relevant information